Podcast + Q&A: Device-Makers Shouldn't Ignore Pharma Quality Metrics Initiative, Attorney Says
This article was originally published in The Gray Sheet
Executive Summary
In a Dec. 9 podcast interview at the Food and Drug Law Institute Enforcement, Litigation and Compliance meeting in Washington, D.C., Alston & Bird partner Cathy Burgess discussed how the FDA’s quality metrics initiative for pharmaceutical companies may also impact expectations for device manufacturers down the line.